{
    "symbol": "CBAY",
    "quarter": 2,
    "year": 2022,
    "date": "2022-08-11 23:16:06",
    "content": " As a reminder, 10 milligrams of daily seladelpar treatment in our prior open-label Phase II and long-term extension study demonstrated consistent sustained and progressive improvements in alkaline phosphatase in the range of approximately 50% reduction after 2 years of treatment with 79% of patients achieving the composite endpoint of alpha less than 1.67x recorded normal, greater than equal to a 15% reduction in a fast and total bilirubin is less than equal to upper limit of normal range."
}